**Hypothesis ID:** GenMet_H1  
**Review decision:** Promising but incomplete  
**Directional assessment:**  
- **Strengths:** Clear data anchor: methionine up (log2FC 3.26) and AMD1 MK enrichment (1.35, PH‑up p=6.55e‑06). The metabolite→polyamine axis is biochemically sound. MK specificity and hypoxia dependence are well supported.  
- **Weaknesses:** Downstream axes remain too broad; the hypothesis lists three plausible routes without committing to one. The working immune‑mediated model is not derived from direct MK‑to‑immune signalling data.  
- **Reasoning quality:** High for the initial metabolic event; the downstream reasoning correctly preserves candidate status but could be misinterpreted as a resolved mechanism.  
- **Appropriate resolution:** Yes – the direction is appropriately broad given the evidence.

**Evidence assessment:**  
- User‑provided data: Direct for metabolite and AMD1 expression.  
- Public data: Not yet verified; GSE289322 may add tissue‑level AMD1 support but does not alter MK‑origin evidence.  
- Literature: AMD1‑polyamine axis in cancer immunometabolism; no direct vascular‑PH‑MK literature.  
- Inference: Polyamines modulate T‑cells and macrophages; stress that this is inferred.  
- Speculation: Polyamine secretion from MKs, local concentration, actual recipient cell type are speculative.

**Major concerns:**  
1. Polyamine secretion by MKs is unproven; they may retain polyamines for cell‑autonomous roles.  
2. The immune‑mediated working model over‑resolves to Th17/macrophage when data only support a metabolic shift.  
3. AMD1 activity (protein/decarboxylated SAM) not measured; it could be transcriptionally upregulated but post‑translationally inhibited.

**Downstream‑axis assessment:**  
- Broad axis: Immune‑mediated, direct vascular‑wall, EV/stromal.  
- Candidate examples: Spermidine‑driven Th17‑like or M2‑like polarization, SMC proliferation.  
- What remains unresolved: The dominant route, exact cell targets.  
- MK‑origin gap: polyamine export, stability, and local concentration unknown.  
- Direction‑specific falsification: MK‑specific Amd1 KO should prevent hypoxia‑induced polyamine accumulation and blunt vascular remodeling (medial thickness). If polyamine levels or remodeling are unchanged, the direction fails.

**Required revisions:**  
- Remove any implication of a settled immune mechanism; explicitly label Th17/IL‑17 as an example candidate, not the working model.  
- Include control experiments to distinguish intracellular polyamine function from extracellular signalling (e.g., inhibitor of polyamine export, AMD1 inhibition in conditioned‑media transfer).

**Experimental critique:**  
- Strong points: MK‑specific KO is feasible and would directly test the AMD1‑to‑remodeling link. Readouts (polyamine LC‑MS, medial thickness) are appropriate.  
- Weak points: No proposed control for non‑MK polyamine sources; AMD1 inhibitor might affect other cells. Missing output: AMD1 activity measurement.  
- Missing controls: AMD1 inhibition in vitro to confirm drug specificity; MK‑derived polyamine secretion assay.  
- Falsification criteria: If MK‑specific Amd1 deletion does not reduce lung tissue polyamines or does not attenuate vascular remodeling, hypothesis is falsified.

**Final recommendation to PI:** Revise – tighten downstream axis language, clarify candidate status, and require AMD1 activity data before progression.

---

**Hypothesis ID:** GenMet_H2  
**Review decision:** Weak  
**Directional assessment:**  
- **Strengths:** Amd2 differential expression is statistically significant; pathway similarity to AMD1 is logical.  
- **Weaknesses:** Very low MK expression (4.4%), no protein evidence, and functional redundancy with AMD1. The hypothesis adds little beyond AMD1.  
- **Reasoning quality:** Adequate, but reliant on additive effect which is not yet supported.  
- **Appropriate resolution:** Yes, but resolution is too fine for current data; Amd2 might be negligible.

**Evidence assessment:**  
- User‑provided data: Amd2 expression pct 4.37%, enrichment 0.93, PH‑up log2FC 2.175, p=0.024.  
- Public data: Pending.  
- Literature: None directly, Amd2 in muscle atrophy not PH.  
- Inference: Cooperative polyamine synthesis is plausible.  
- Speculation: Protein expressed and active in MKs, dual targeting gives greater effect.

**Major concerns:**  
- The low expression raises question of biological significance; could be noise or a minor subset.  
- Without direct measurement of Amd2 protein or its contribution to polyamine flux, the hypothesis is speculative.  
- Risk of false‑positive due to multiple testing in low‑expression genes.

**Downstream‑axis assessment:** Same as GenMet_H1; axes unchanged. Falsification requires dual Amd1/Amd2 knockout showing additive benefit over Amd1 alone. If not, Amd2 irrelevant.

**Required revisions:** Not recommended for revision; deprioritize. If pursued, must include Amd2 protein detection and confirm synthetic redundancy.

**Experimental critique:** Feasible but high bar: Amd2 KO must show additional effect, otherwise confounding many experiments. Missing control: Amd2 overexpression in MKs to test sufficiency.

**Final recommendation to PI:** Deprioritize – the hypothesis does not independently advance the AMD1 axis; it is a modifier with weak data support. Merge into AMD1 hypothesis as a secondary note.

---

**Hypothesis ID:** GenMet_H3  
**Review decision:** Reject  
**Directional assessment:**  
- **Strengths:** Conceptually novel linking methionine to epigenetics.  
- **Weaknesses:** Dnmt3b expression in MKs is low, not significantly PH‑up, and not MK‑enriched. No evidence of methylation change.  
- **Reasoning quality:** Poor – overinterprets non‑significant expression data; causal chain is highly speculative.  
- **Appropriate resolution:** No, the resolution is inappropriate given minimal MK expression.

**Evidence assessment:**  
- User‑provided data: Dnmt3b pct 2.62%, enrichment 0.19, PH log2FC 1.59 p=0.212 – not significant.  
- Public data: No support.  
- Literature: Methionine‑methylation axis in immune cells but no MK‑specific.  
- Inference: Weak.  
- Speculation: Entirely speculative; no direct evidence that methionine increases SAM/SAH ratio or alters methylation in MKs.

**Major concerns:**  
- The core enzyme is not convincingly expressed or regulated in MKs; the hypothesis lacks a data anchor.  
- DNA methylation assays would be required but the hypothesis does not define which loci or functional outcome.

**Downstream‑axis assessment:** Irrelevant given evidence failure.

**Required revisions:** N/A; do not pursue.

**Experimental critique:** MK‑specific Dnmt3b KO would be informative but is a fishing expedition; no specific target genes defined. Falsification criteria too vague.

**Final recommendation to PI:** Reject – insufficient evidence to support.

---

**Hypothesis ID:** GenMet_H4  
**Review decision:** Weak  
**Directional assessment:**  
- **Strengths:** Retinoic acid is highly up; interesting immunomodulatory molecule.  
- **Weaknesses:** Cyp26b1 expression in MKs is low, not significantly PH‑up, and the metabolite accumulation contradicts a catabolism‑driven hypothesis (RA up, not down).  
- **Reasoning quality:** Forced; attempts to reconcile RA increase with degradation by MKs without experimental support.  
- **Appropriate resolution:** No, the direction is not clearly anchored; RA increase might reflect increased synthesis, not reduced degradation.

**Evidence assessment:**  
- User‑provided data: RA up, Cyp26b1 expression trend but p=0.253 not significant.  
- Public data: None.  
- Literature: Cyp26b1 in retinoid homeostasis; no MK‑PH link.  
- Inference: If MKs degrade RA, local RA would decrease, but we see increase – inferring MK‑mediated degradation is counter‑intuitive.  
- Speculation: MKs could be upregulating Cyp26b1 to compensate, but the net effect is still RA increase; unclear how that would promote remodeling.

**Major concerns:**  
- The hypothesis is internally inconsistent with the primary data.  
- No direct measurement of RA‑degrading activity.  
- Low MK expression undermines MK specificity.

**Downstream‑axis assessment:** Not applicable.

**Required revisions:** None.

**Experimental critique:** MK‑specific Cyp26b1 KO unlikely to yield interpretable results given the data conflict.

**Final recommendation to PI:** Reject – not supported by user data and runs counter to observed metabolite change.

---

**Hypothesis ID:** Gen1_H1 (inosine/Pnp adenosine receptor vascular)  
**Review decision:** Promising but incomplete  
**Directional assessment:**  
- **Strengths:** Strong metabolite‑enzyme connection: inosine up 3.82x, Pnp significantly upregulated in MKs (log2FC 1.74, p=3.81e‑06). Adenosine receptors are known to influence vascular remodeling.  
- **Weaknesses:** The downstream axis is direct vascular‑wall but does not distinguish between inosine and adenosine effects; A2B receptor may have dual pro‑/anti‑remodeling roles. No evidence of extracellular adenosine generation from MKs.  
- **Reasoning quality:** Good; the pathway logic is sound, and it acknowledges uncertainty about receptor subtype and net effect.  
- **Appropriate resolution:** Broad enough; the exact receptor and target cell are unresolved.

**Evidence assessment:**  
- User‑provided data: Inosine, Pnp expression, and NT5C2 up indirectly support. Not adenosine directly.  
- Public data: GSE289322 can validate Pnp tissue level; not yet available.  
- Literature: Adenosine‑A2B in PH, VSMC proliferation.  
- Inference: MK‑derived inosine converted to adenosine by ectonucleotidases.  
- Speculation: Concentration of adenosine in perivascular space; net pathological role.

**Major concerns:**  
1. Adenosine can be vasoprotective; the hypothesis must specify what tips the balance to harmful.  
2. No direct measurement of adenosine release from MKs.  
3. The hypothesized endothelial dysfunction and VSMC proliferation via A2B need more precise mapping.

**Downstream‑axis assessment:**  
- Broad axis: Direct vascular‑wall (adenosine receptors).  
- Candidate examples: A2B on VSMC, A2A on endothelium.  
- What remains unresolved: Receptor subtype dominance, net effect, role of extracellular conversion.  
- MK‑origin gap: Adenosine/inosine export, local concentrations.  
- Falsification: MK‑specific Pnp KO should reduce perivascular adenosine/inosine and blunt remodeling. If A2B antagonist fails to attenuate remodeling, the direct vascular‑wall route is refuted.

**Required revisions:**  
- Include a control experiment to measure adenosine/inosine in BAL or interstitial fluid.  
- Address potential protective adenosine effects and define experimental conditions where pathological predominates.

**Experimental critique:**  
Strong points: MK‑specific Pnp deletion feasible; hemodynamic and morphometric readouts appropriate. Weak points: Receptor blockade alone may not isolate MK source; need MK‑secretome transfer model. Missing controls: Vehicle‑treated MK‑KO with A2B agonist rescue. Falsification criteria: If MK‑Pnp KO does not alter vascular phenotype, hypothesis unsupported.

**Final recommendation to PI:** Revise – strengthen the distinction between inosine and adenosine and include rescue experiments.

---

**Hypothesis ID:** Gen1_H2 (methylglyoxal RAGE)  
**Review decision:** Weak  
**Directional assessment:**  
- **Strengths:** Pyruvaldehyde (methylglyoxal) is highly upregulated (4.43x).  
- **Weaknesses:** No enzyme gene linked in evidence context; the hypothesis invokes Glo1 without user data. The MK‑specific production is speculative.  
- **Reasoning quality:** Overclaiming; methylglyoxal is a common glycolytic byproduct, not a defined MK‑specific mediator.  
- **Appropriate resolution:** No, it assumes MK source without direct support.

**Evidence assessment:**  
- User‑provided data: Methylglyoxal up in MK metabolomics; no Glo1 expression data.  
- Public data: None.  
- Literature: RAGE in PH, methylglyoxal in diabetes.  
- Inference: Glycolysis in hypoxic MKs leads to methylglyoxal.  
- Speculation: MK‑derived methylglyoxal dominates perivascular pool; Glo1 downregulated.

**Major concerns:**  
- Missing critical data: Glo1 expression in MKs, MK glycolysis rate, methylglyoxal secretion.  
- Methylglyoxal is highly reactive; majority likely intracellular.  
- The hypothesis cannot be verified with current data.

**Downstream‑axis assessment:** Not robust.

**Required revisions:** Need to query Seurat for Glo1 and lactate dehydrogenase; show methylglyoxal secretion from hypoxic MKs in vitro.

**Experimental critique:** MK‑specific Glo1 overexpression would be lengthy; not feasible without foundational data. Missing controls: methylglyoxal scavenger in MK‑specific manner.

**Final recommendation to PI:** Deprioritize – data gap too large; do not advance without primary evidence of MK Glo1 expression and methylglyoxal release.

---

**Hypothesis ID:** Gen1_H3 (retinoic acid Cyp26b1 VSMC)  
Similar to GenMet_H4; Weak; same issues. RA up, Cyp26b1 non‑significant, contradictory. Reject.

---

**Generation 1 H4** not provided; cannot review.

---

**Hypothesis ID:** Gen2_H1 (AMD1 polyamine M2 macrophage fibrosis)  
**Review decision:** Promising but incomplete  
**Directional assessment:**  
- **Strengths:** Uses the same strong AMD1 data; provides a specific downstream axis (M2 macrophage polarization).  
- **Weaknesses:** The specific M2/T
